logo

For the Inventor, By the Inventor

Fair Lawn, NJ, United States of America

Xiaoming Xu

This inventor holds 3 USPTO granted patents and 3 published patent applications. Top assignee: Columbia University. Active years: 2021-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Xiaoming Xu. Retrieved from https://idiyas.com/inventor/xiaoming-xu-5a302h4b

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 66.7

Average Co-Inventor Count = 5.1

ph-index = 1


Company Filing History:

goldMedal3 out of 2,554 
 
Columbia University
 patents

Years Active: 2021-2025

Loading Chart...
3 patents (USPTO):Explore Patents
1. 12492207 - Compounds, pharmaceutical formulations, and methods for treatment of cancer (2025-12-09),
2. 11459306 - Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia (2022-10-04),
3. 10882863 - Compounds for reducing c-Myc in c-Myc overexpressing cancers background (2021-01-05),

Title: Innovations in Cancer Treatment by Inventor Xiaoming Xu

Introduction

Xiaoming Xu is a notable inventor based in Fair Lawn, NJ (US), recognized for his contributions to cancer treatment through innovative compounds and methods. With a total of two patents, his work focuses on addressing critical challenges in treating hematological cancers.

Latest Patents

Xiaoming Xu's latest patents include significant advancements in the treatment of T-cell acute lymphoblastic leukemia. One patent discloses compounds, compositions, and methods for administering these compounds to patients in need. This innovation also encompasses compounds that inhibit two phosphoinositide 3-kinase (PI3K) isoforms, which are crucial in the treatment of non-Hodgkin lymphoma. Another patent introduces new compounds aimed at reducing c-Myc expression, particularly in aggressive B- and T-cell lymphomas. These compounds can be combined with adjunct c-Myc inhibitor agents to enhance the effectiveness of cancer therapies.

Career Highlights

Xiaoming Xu is affiliated with Columbia University, where he continues to advance research in cancer treatment. His work has garnered attention for its potential to improve patient outcomes in hematological cancers.

Collaborations

Xiaoming Xu collaborates with esteemed colleagues, including Donald W. Landry and Shi-Xian Deng, contributing to a rich environment of innovation and research.

Conclusion

Xiaoming Xu's innovative work in cancer treatment exemplifies the impact of research and invention in the medical field. His patents reflect a commitment to developing effective therapies for challenging diseases.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…